Fredun Pharma Allots 44,000 Shares Post Warrant Conversion

Fredun Pharmaceuticals Ltd has allotted 44,000 equity shares to non-promoter allottees following the conversion of 14,667 warrants. This conversion was made possible after the company's 1:2 bonus issue, which proportionately adjusted the entitlement of outstanding warrants. The warrants were initially allotted on December 29, 2025, on a preferential basis. The conversion exercise, completed on October 23, 2026, involved the payment of the balance consideration by the warrant holders. The newly allotted shares rank pari passu with existing equity shares.